GlobeNewswire Inc.··Faruqi & Faruqi, LlpAquestive Therapeutics Faces FDA Setback on Anaphylm Application; Investor Claims Under Review
Aquestive Therapeutics' stock plunged 40% after FDA cited major deficiencies in its Anaphylm anaphylaxis treatment application. Shareholder lawsuit investigation underway over disclosure adequacy.
AQSTstock declinesecurities investigation